Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives’ on COVID-19 and health care service during the pandemic

Moum, Kristian Marling; Moum, Bjørn; Opheim, Randi

doi:10.1080/00365521.2021.1901308

Cited by 7 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subgroup analysis indicated a prevalence of 9.43% (95% CI − 13.86 to 32.73%; n = 10 studies) of COVID-19 among the patients with CD 26 – 28 , 34 , 35 , 45 , 46 , 73 , 76 , 84 and 8.58% (95% CI − 8.22 to 25.38; n = 10 studies) among those patients with UC 27 , 28 , 34 , 35 , 45 , 46 , 55 , 73 , 76 , 84 . This analysis indicated that, type of IBD was not a contributing factor to the heterogeneity as there was no change in the level of heterogeneity even after a subgroup analysis (Fig.…”

Section: Resultsmentioning

confidence: 99%

Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis

Abdulla

Mohammed

AlQamish

et al. 2022

Sci Rep

View full text Add to dashboard Cite

There is conflicting evidence concerning the effect of inflammatory bowel disease (IBD) on COVID-19 incidence and outcome. Hence, we aimed to evaluate the published evidence through a systematic review process and perform a meta-analysis to assess the association between IBD and COVID-19. A compressive literature search was performed in PubMed/Medline, Scopus, Embase, and Cochrane Library from inception to July 2021. A snowball search in Google, Google Scholar, Research Gate, and MedRxiv; and bibliographic research were also performed to identify any other relevant articles. Quantitative observational studies such as cohort, cross-sectional, and case–control studies that assessed the incidence, risk, and outcomes of COVID-19 among the adult IBD patients published in the English language, were considered for this review. The incidence and risk of COVID-19, COVID-19 hospitalization, the severity of COVID-19, and mortality were considered as the outcomes of interest. The Joanna Briggs Institute critical appraisal checklist was used for quality assessment. A subgroup and sensitivity analysis were performed to explore the heterogeneity and robustness of the results, respectively. A total of 86 studies out of 2828 non-duplicate records were considered for this meta-analysis. The studies were single or multicentric internationally from settings such as IBD centres, medical colleges, hospitals, or from the general public. Most of the studies were observed to be of good quality with an acceptable risk of bias. The pooled prevalence of COVID-19, COVID-19 hospitalization, severe COVID-19, and mortality in the IBD population were 6.10%, 10.63%, 40.43%, and 1.94%, respectively. IBD was not significantly (p > 0.05) associated with the risk of COVID-19, COVID-19 hospitalization, severe COVID-19, and mortality. In contrast, ulcerative colitis was significantly associated with a higher risk of COVID-19 (OR 1.37; p = 0.01), COVID-19 hospitalization (OR 1.28; p < 0.00001), and severe COVID-19 (OR 2.45; p < 0.0007). Crohn’s disease was significantly associated with a lesser risk of severe COVID-19 (OR 0.48; p = 0.02). Type of IBD was a potential factor that might have contributed to the higher level of heterogeneity. There was a significant association between ulcerative colitis and increased risk of COVID-19, COVID-19 hospitalization, and severe COVID-19 infection. This association was not observed in patients with Crohns' disease or in those diagnosed non-specifically as IBD.

show abstract

Section: Resultsmentioning

confidence: 99%

Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis

Abdulla

Mohammed

AlQamish

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In our study, however, no GI symptoms were observed. This might be explained by the median age in our sample, which was higher than the median age in the metanalysis by Badal et al, even when adjusted to include only the pediatric patients (15 years [7][8][9][10][11][12][13][14][15][16][17][18] compared to 8 years [6][7][8][9][10]).…”

Section: Discussion/conclusionmentioning

confidence: 79%

“…Until the moment, the knowledge concerning the risk of COVID-19 in inflammatory bowel disease (IBD) patients, particularly pediatric IBD patients, is still scarce [ 8 , 9 ]. Recent studies seem to show that IBD patients are at no greater risk than the general population [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Impact of COVID-19 in Pediatric Patients and Young Adults with Inflammatory Bowel Disease

Magalhães

Granado²,

Manuel

et al. 2022

GE Port J Gastroenterol

View full text Add to dashboard Cite

Introduction: Acute COVID-19 in pediatric and young adult patients tends to be milder in severity compared to adult infection. Recent studies seem to show that inflammatory bowel disease (IBD) patients are at no greater risk than the general population. We aim to describe our experience in the follow-up of pediatric and young adult patients with IBD followed in our center and determine possible risk factors of said population for severe COVID-19. Methods: We performed a retrospective study of all patients aged under 25 years followed for IBD at the Unit of Pediatric Gastroenterology in a tertiary center between December 2019 and April 2021 evaluating the incidence of COVID-19 and characterization of positive cases. Results: Of the 268 participants, 24 had COVID-19: the mean age was 19 years old and gender had an equal distribution; 75% (n = 18) had Crohn’s disease, whereas only 25% (n = 6) had ulcerative colitis. Most patients were in clinical remission (n = 21). The majority of patients were under treatment with a tumor necrosis factor (TNF) antagonist (58%, n = 14), mainly infliximab, and most had no comorbidities other than IBD (83%). Regarding COVID-19, 17% of the patients were asymptomatic while the rest had only mild symptoms. There were no reported gastrointestinal complaints, no complications nor hospitalizations. Most patients did not require interruption of their IBD treatment. Conclusions: Our data suggest that pediatric and young adult IBD patients have a low risk for complications and hospitalization, regardless of IBD treatment. We believe that this experience is encouraging and allows for safe counseling regarding treatment options and school attendance in pediatric and young adult IBD patients.

show abstract

“…This study focused upon mitigation techniques such as quarantine and avoiding in-person visits. 8 No data were obtained surrounding patient prioritization of research questions based on their fears. A second web-based survey on disease-related experiences of patients with IBD and concerns during the COVID-19 pandemic showed that 62% feared an increased risk of severe COVID-19.…”

Section: Discussionmentioning

confidence: 99%

A Patient-Prioritized Agenda for Information Needs During the COVID-19 Pandemic: A Qualitative Study of Patients With Inflammatory Bowel Disease

Long

Grewe²,

Cerciello

et al. 2021

Crohn's &Amp; Colitis 360

View full text Add to dashboard Cite

Background/Aims Patients with inflammatory bowel disease (IBD) may be at risk for complications due to the COVID-19 pandemic. We performed a qualitative study to better understand IBD patient experiences and concerns when navigating the COVID-19 pandemic, with the goal of prioritizing patients’ information needs. Methods We conducted a series of semi-structured virtual focus groups at 6 months, then member-checking focus groups 1 year into the COVID-19 pandemic. We included questions on patients’ experiences navigating the pandemic with IBD, differences in their experience as compared to peers, their concerns and fears, as well as preferred information sources. Transcribed focus groups were coded and content-analyzed to summarize key areas of interest and identify themes. We focused on four areas in our content analysis process: fears, challenges, information preferences and research questions. Results A total of 26 IBD patient participants were included in the initial focus groups. Findings highlighted the many challenges faced by patients during the COVID-19 pandemic, ranging from access (bathrooms, medications, healthcare) to significant fears and concerns surrounding medications used for IBD worsening risks of COVID-19. Research questions of importance to patients centered on understanding risks for COVID-19 complications, particularly pertaining to medication utilization, with a shift over time towards understanding COVID-19 vaccination. In our member checking focus groups (n=8 participants), themes were reiterated, with a central focus of research questions pertaining to COVID-19 vaccination. Conclusions Information needs for patients during the COVID-19 pandemic centered upon understanding disease specific risks. Identified challenges and fears will inform future research agendas and communication with patients.

show abstract

Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives’ on COVID-19 and health care service during the pandemic

Cited by 7 publications

References 11 publications

Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis

Inflammatory bowel disease and COVID-19 outcomes: a meta-analysis

Impact of COVID-19 in Pediatric Patients and Young Adults with Inflammatory Bowel Disease

A Patient-Prioritized Agenda for Information Needs During the COVID-19 Pandemic: A Qualitative Study of Patients With Inflammatory Bowel Disease

Contact Info

Product

Resources

About